Head-to-head evidence
CT-996 vs regor GLP-1
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CT-996
Developed by Roche
NCT07081958 · Phase 2 · completed
The study randomized 352 participants to placebo or one of seven RO7795081 dosing regimens, with participants and investigators blinded. Its primary endpoint was the clinical measure of percent change in body weight at Week 30, but no results or statistical comparison have been posted, so the endpoint cannot yet be classified as met or missed.
Next expected readout: December 2026 · NCT06982131 (registry estimate)
regor GLP-1
Developed by Regor Pharmaceuticals
NCT06867718 · Phase 2 · completed
The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-996's landscape · regor GLP-1's landscape